According to Taro Pharmaceutical's latest financial reports the company has $0.90 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-03-31 | $0.85 B | 3.6% |
2022-03-31 | $0.82 B | -19.82% |
2021-03-31 | $1.02 B | -7.67% |
2020-03-31 | $1.10 B | 5.66% |
2019-03-31 | $1.04 B | -26.24% |
2018-03-31 | $1.42 B | 2.59% |
2017-03-31 | $1.38 B | 12.87% |
2016-03-31 | $1.22 B | 33.55% |
2015-03-31 | $0.91 B | 45.53% |
2014-03-31 | $0.63 B | 14.3% |
2013-03-31 | $0.55 B | |
2011-12-31 | $0.24 B | 173.21% |
2010-12-31 | $88.83 M | -22.26% |
2009-12-31 | $0.11 B | 44.98% |
2008-12-31 | $78.82 M | 74.45% |
2007-12-31 | $45.18 M | 178.01% |
2006-12-31 | $16.25 M | -77.72% |
2005-12-31 | $72.96 M | -26.02% |
2004-12-31 | $98.63 M | -38.02% |
2003-12-31 | $0.15 B | 21.73% |
2002-12-31 | $0.13 B | -14.65% |
2001-12-31 | $0.15 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 2,441.19% | ๐บ๐ธ USA |
Novartis NVS | $13.96 B | 1,447.52% | ๐จ๐ญ Switzerland |
Pfizer PFE | $12.69 B | 1,306.54% | ๐บ๐ธ USA |
Merck MRK | $7.09 B | 686.18% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $6.35 B | 604.36% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | $3.22 B | 257.56% | ๐ฎ๐ฑ Israel |